
The delivery of cancer chemotherapy is often zzso because of dose reductions and delays related to various toxic zzso These result in a decrease of the dose intensity as well as of the relative dose intensity of a given regimen compared to a reference zzso In retrospective studies, such modifications have been shown to zzso influence the therapeutic results in many clinical zzso The ability of zzso growth factors to reduce zzso zzso and its associated infectious complications allows better zzso delivery of the zzso zzso The potential therapeutic impact of this effect remains to be determined in prospective zzso 

